1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 20 APRIL 2015

CNS Drug News 20 APRIL 2015

  • April 2015
  • -
  • Espicom Business Intelligence
  • -
  • 28 pages

Industry Trend Analysis - First Generic Copaxone Approved But Launch Remains Uncertain
Industry Brief - Adamas Issued US Patent
Industry Brief - FDA Grants ODD To Adamas' ADS-5102 For LID Associated With PD
Industry Brief - US PTO Declares Interference Between Forward Pharma And Biogen
Industry Brief - Receptos Completes Enrolment In RADIANCE Phase III Trial Of Ozanimod In RMS
Industry Trend Analysis - Increased Investment Will Advance ALS Pipeline
Industry Brief - Horizon Receives FDA Fast Track Designation For Actimmune In FA
Industry Brief - Athersys Reports Results From MultiStem Phase II Study For Ischaemic Stroke
Industry Brief - StemCells Completes Enrolment Of First Cohort In Phase II Study For Cervical SCI
Industry Brief - Bionomics Initiates Phase II Trial Of BNC210 For Anxiety
Industry Brief - Health Canada Warns ADHD Drugs May Increase Risk Of Suicidal Thoughts/Behaviours
Industry Brief - Invega Sustenna Effective Six Months Longer Than Common Oral Antipsychotics In Schizophrenia
Industry Brief - Shire/FDA Reach Agreement On Regulatory Path For SHP465
Industry Brief - Three-Month Paliperidone Palmitate Significantly Delays Time To Relapse In Schizophrenia
Industry Brief - Alkermes Reports Positive Top-Line Results From Complete Six-Month Phase II Trial Of ALKS 3831
Industry Trend Analysis - Litigation Settlement Proves Viability Of Gralise Business Model
Industry Brief - Pernix Obtains Six Months US Paediatric Exclusivity For Treximet
Industry Brief - Dr Reddy's/Promius File Three NDAs With FDA
Industry Brief - Aurobindo Gains US Atracurium Approvals
Industry Brief - Charleston Completes Enrolment In Phase III Study Of CL-108
Industry Brief - Perrigo To Launch Exalgo Equivalent Following FDA Approval
Industry Brief - Sixth US Patent Protecting Trokendi XR Issued
Industry Brief - CFDA Approves IND For D-Pharm's Anti-Epileptic Drug In China
Industry Brief - First Patient Treated Under Phase III Expanded Access Protocol To Evaluate SAGE-547 In SRSE
Industry Trend Analysis - Patent Challenge Exposes Qsymia's Weaknesses
Industry Brief - Eisai/Arena Complete Registrational Trials Of Lorcaserin ER Formulation
Industry Brief - Acacia Initiates Phase III Combination Prophylaxis Study With APD421 In PONV
Industry Brief - Neurocrine/MTP Enter Deal For VMAT2 Inhibitor In Japan And Other Select Asian Markets
Industry Brief - Lundbeck/Ovid Enter Exclusive Worldwide Licensing Agreement For Gaboxadol
Industry Brief - Neurotrope Receives FDA ODD For Bryostatin In FXS
Industry Trend Analysis - J&J's Neuroscience Pipeline Will Need Investment
Industry Trend Analysis - H216 Will Be Key For High Risk/High Reward Opexa
Industry Brief - Teva To Acquire Auspex Pharmaceuticals
Industry Brief - Egalet Raises Funds For Commercialisation Of Approved Products And R&D
Industry Brief - Voyager Raises USD60mn To Advance Pipeline For CNS Diseases
Industry Brief - Janssen Completes Divestiture Of US Licence Rights To Nucynta Franchise
Industry Brief - Alzheon Raises Funds To Advance ALZ-801 Toward Pivotal Clinical Study In AD
Industry Brief - Cynapsus Raises Funds Through Private Placement
Industry Brief - UCB To Sell Established Brands Portfolio In India To Dr Reddy's; Focus On Core Business
Industry Brief - Neuronascent Secures Financing For Development Of AD Therapeutic
Industry Brief - Edge Raises Funds To Advance EG-1962 And Earlier Stage Pipeline
Industry Brief - CNS Conferences - July 2015

Table Of Contents

CNS Drug News 20 APRIL 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.